Detalhe da pesquisa
1.
Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities.
Acta Pharmacol Sin;
44(11): 2322-2330, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37328649
2.
Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain.
FEBS Open Bio;
12(9): 1644-1656, 2022 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35792784